A global trial that will look into a new application method for one of the most commonly-used hair loss drugs is now recruiting volunteers to take part.
The study been announced by Swiss pharmaceutical company Polichem, and the randomised, double-blind Phase 3 trial is hoping to enlist an impressive 450 volunteers who will be involved over a six-month period.
The trial is certainly of interest to the medical community as Polichem has announced that it will be using a topical version of the drug finasteride 1mg, one of just two MHRA licensed and FDA approved medications for the treatment of Male Pattern Hair Loss. Currently this drug is taken orally (its only approved format) in order to help prevent baldness.
At more than 60 sites across Belgium, Germany, Spain, Russia and Hungary, the Polichem trial will explore the clinical efficacy and safety of what has been named P-3074. The company further describes this as a cutaneous spray solution.
Participants must all be aged between 18 and 40, and they must be displaying moderate to advanced hair thinning that registers as type III vertex, IV or V on the Norwood Hamilton scale. They must also be willing to have a tiny tattoo on their scalp, so that testers can easily return to the same area on their scalp during the study.
In an earlier Polichem trial involving 60 men with androgenetic alopecia, Essex-based testers employed by the company announced that Ultraviolet light would be used during treatment, apparently to cause a reaction that would make the drug more effective. There is no specific mention of UV light being used this time around.
The finasteride used in the trial will be a 0.25 per cent solution, and a percentage of the volunteers will be given the more traditional oral version of finasteride in its usual 1mg doses so that results can be compared.
There are a long list of reasons why people may be excluded from this particular trial, including abnormal scalp findings, hair transplant surgery and a history of infertility. Use of any of a large number of drugs would render an applicant unsuitable, too, including finasteride and also minoxidil – the other MHRA licensed and FDA approved Male Hair Loss Treatment. The study is slated for completion by the end of 2017.
Current hair loss solutions
When seeking a non-surgical hair loss solution for Male Pattern Baldness, men are assessed then diagnosed by a specialist who then provides them with a comprehensive list of options tailored to their medical requirements, level and pattern of shedding.
Alongside the key topical and oral medications, additional hair growth supporting products can be useful.
While the Polichem trial is certainly interesting, for men worried about a thinning crown or receding hairline, there are already proven hair loss solutions that can help to both stop hair falling out and also encourage new growth. The best place to start for anyone concerned about losing their hair and wanting to explore suitable solutions, is with a professional consultation.
The Belgravia Centre is an organisation specialising in hair growth and hair loss prevention with two clinics and in-house pharmacies in Central London, UK. If you are worried about hair loss you can arrange a free consultation with a hair loss expert or complete our Online Consultation Form from anywhere in the world. View our Hair Loss Success Stories, which includes the world’s largest gallery of hair growth comparison photos and demonstrates the levels of success that so many of Belgravia’s patients achieve. You can also phone 020 7730 6666 any time to arrange a free consultation.